Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

Breast Cancer Research and Treatment

Volumn 124, Issue 2, 2010, Pages 433-439

  Yao, Song ^a   Barlow, William E ^b   Albain, Kathy S ^c   Choi, Ji Yeob ^d   Zhao, Hua ^a   Livingston, Robert B ^e   Davis, Warren ^a   Rae, James M ^f   Yeh, I Tien ^g   Hutchins, Laura F ^h   Ravdin, Peter M ^g   Martino, Silvana ⁱ   Lyss, Alan P ^j   Kent Osborne, C ^k   Abeloff, Martin D ^l   Hortobagyi, Gabriel N ^m   Hayes, Daniel F ^f   Ambrosone, Christine B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Statistical Center   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d Inje University College of Medicine   (South Korea)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j MISSOURI BAPTIST MEDICAL CENTER   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Disease free survival; Polymorphism; SNP; SOD2; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ALLELE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOUTHWESTERN UNITED STATES; SUPEROXIDE DISMUTASE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649325635     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0840-0     Document Type: Article

References (23)

1. J Ahn CB Ambrosone PA Kanetsky C Tian TA Lehman S Kropp I Helmbold D von Fournier W Haase ML Sautter-Bihl F Wenz J Chang-Claude 2006 Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer Clin Cancer Res 12 7063 7070 1:CAS:528:DC%2BD28Xht1Kns7nP 10.1158/1078-0432.CCR-06- 0039 17145829 (Pubitemid 44974505)
2. CB Ambrosone JL Freudenheim PA Thompson E Bowman JE Vena JR Marshall S Graham R Laughlin T Nemoto PG Shields 1999 Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer Cancer Res 59 602 606 1:CAS:528:DyaK1MXhtV2rtr0%3D 9973207
3. CB Ambrosone J Ahn KK Singh H Rezaishiraz H Furberg C Sweeney B Coles A Trovato 2005 Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer Cancer Res 65 1105 1111 1:CAS:528:DC%2BD2MXhtVWnurY%3D 15705913
4. CB Ambrosone WE Barlow W Reynolds RB Livingston IT Yeh JY Choi W Davis JM Rae L Tang LR Hutchins PM Ravdin S Martino CK Osborne AP Lyss DF Hayes KS Albain 2009 Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897 J Clin Oncol 27 4973 4979 1:CAS:528:DC%2BD1MXhsVCrsr%2FL 10.1200/JCO.2009.21.8669 19752340
5. M Bastaki K Huen P Manzanillo N Chande C Chen JR Balmes IB Tager N Holland 2006 Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans Pharmacogenet Genom 16 279 286 1:CAS:528:DC%2BD28Xit12ht7o%3D 10.1097/01.fpc.0000199498.08725.9c
6. MA Bewick MS Conlon RM Lafrenie 2006 Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer J Clin Oncol 24 5645 5651 1:CAS:528:DC%2BD2sXhtVChsrk%3D 10.1200/JCO.2006.05.9923 17116943 (Pubitemid 46631304)
7. G Bonadonna E Brusamolino P Valagussa A Rossi L Brugnatelli C Brambilla M De Lena G Tancini E Bajetta R Musumeci U Veronesi 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410 1:STN:280:DyaE287gtVKrtA%3D%3D 10.1056/NEJM197602192940801 1246307
8. JM Bull DC Tormey SH Li PP Carbone G Falkson J Blom E Perlin R Simon 1978 A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy Cancer 41 1649 1657 1:STN:280:DyaE1c7mslSlsA%3D%3D 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J 348293 (Pubitemid 8335369)
9. JY Choi SA Nowell JG Blanco CB Ambrosone 2006 The role of genetic variability in drug metabolism pathways in breast cancer prognosis Pharmacogenomics 7 613 624 1:CAS:528:DC%2BD28XmvV2jtro%3D 10.2217/14622416.7.4. 613 16753008 (Pubitemid 43891417)
10. JY Choi WE Barlow KS Albain CC Hong JG Blanco RB Livingston W Davis JM Rae IT Yeh LF Hutchins PM Ravdin S Martino AP Lyss CK Osborne MD Abeloff DF Hayes CB Ambrosone 2009 Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial Clin Cancer Res 15 5258 5266 1:CAS:528:DC%2BD1MXpvFeitL4%3D 10.1158/1078-0432.CCR-09-0685 19671875
11. P Costantini E Jacotot D Decaudin G Kroemer 2000 Mitochondrion as a novel target of anticancer chemotherapy J Natl Cancer Inst 92 1042 1053 1:CAS:528:DC%2BD3cXlsVChtbs%3D 10.1093/jnci/92.13.1042 10880547
12. SA Glynn BJ Boersma TM Howe H Edvardsen SB Geisler JE Goodman LA Ridnour PE Lonning AL Borresen-Dale B Naume VN Kristensen SJ Chanock DA Wink S Ambs 2009 A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide Clin Cancer Res 15 4165 4173 1:CAS:528:DC%2BD1MXntlOisb0%3D 10.1158/1078-0432.CCR-09-0119 19509150
13. S Green GR Weiss 1992 Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 10 239 253 1:STN:280:DyaK3s7jvV2jsw%3D%3D 10.1007/BF00944177 1487397 (Pubitemid 23008970)
14. LF Hutchins SJ Green PM Ravdin D Lew S Martino M Abeloff AP Lyss C Allred SE Rivkin CK Osborne 2005 Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102 J Clin Oncol 23 8313 8321 1:CAS:528:DC%2BD2MXhtlWhtrjK 10.1200/JCO.2005.08.071 16293862
15. AM Janssen CB Bosman W van Duijn MM Oostendorp-van de Ruit FJ Kubben G Griffioen CB Lamers JH van Krieken CJ van de Velde HW Verspaget 2000 Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer Clin Cancer Res 6 3183 3192 1:CAS:528:DC%2BD3cXmsVOmtrY%3D 10955802
16. N Kuptsova J Chang-Claude S Kropp I Helmbold P Schmezer D von Fournier W Haase ML Sautter-Bihl F Wenz K Onel CB Ambrosone 2008 Genetic predictors of long-term toxicities after radiation therapy for breast cancer Int J Cancer 122 1333 1339 1:CAS:528:DC%2BD1cXit1yhsLc%3D 10.1002/ijc.23138 18027873 (Pubitemid 351287234)
17. H Li PW Kantoff E Giovannucci MF Leitzmann JM Gaziano MJ Stampfer J Ma 2005 Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer Cancer Res 65 2498 2504 1:CAS:528:DC%2BD2MXisFGnsLY%3D 10.1158/0008-5472.CAN-04-3535 15781667 (Pubitemid 40490163)
18. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
19. SY Park I Chang JY Kim SW Kang SH Park K Singh MS Lee 2004 Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase J Biol Chem 279 7512 7520 1:CAS:528:DC%2BD2cXhsFejsrg%3D 10.1074/jbc.M307677200 14660625 (Pubitemid 38294629)
20. JM Rae KE Cordero JO Scheys ME Lippman DA Flockhart MD Johnson 2003 Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples Pharmacogenetics 13 501 507 1:CAS:528:DC%2BD3sXlvV2jtL4%3D 10.1097/00008571-200308000-00008 12893988 (Pubitemid 37034592)
21. S Shimoda-Matsubayashi H Matsumine T Kobayashi Y Nakagawa-Hattori Y Shimizu Y Mizuno 1996 Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease Biochem Biophys Res Commun 226 561 565 1:CAS:528:DyaK28Xls1yiurk%3D 10.1006/bbrc.1996.1394 8806673 (Pubitemid 26331940)
22. A Sutton H Khoury C Prip-Buus C Cepanec D Pessayre F Degoul 2003 The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria Pharmacogenetics 13 145 157 1:CAS:528:DC%2BD3sXjtVygsbs%3D 10.1097/00008571-200303000-00004 12618592 (Pubitemid 36324244)
23. A Sutton A Imbert A Igoudjil V Descatoire S Cazanave D Pessayre F Degoul 2005 The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability Pharmacogenet Genom 15 311 319 1:CAS:528:DC%2BD2MXjslyqurs%3D 10.1097/01213011-200505000-00006